lotiglipron Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: Vendor-neutral scientific reference catalog record for lotiglipron.

Investigational small-molecule glucagon-like peptide-1 receptor agonist compound Reference needs_revision Best effort · source review pending

Also known as: PF-07081532, Lotiglipron tromethamine

Open in Calculator ← Compound Index All Tools

Best-effort research profile: this record has not passed full two-source scientific verification. Descriptive fields, research protocols, storage/handling notes, and interaction guidance below are shown with their evidence labels, but calculator presets and exact dosing math remain hidden until the record is verified or reaches Community-Supported status.

Quick Facts

Reference Sizes

Not standardized / source review pending

Best-Effort Research Profile

Lotiglipron is a selective small-molecule GLP-1 receptor agonist investigated as a once-daily oral compound. Clinical studies evaluated its pharmacokinetics, tolerability, glycemic effects, and effects on body weight. Clinical development was terminated after subsequent studies identified elevated transaminases and unexpectedly high drug exposures in some participants.

Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.

Research Profile

Half-Life

Mean terminal plasma half-life of approximately 20.70–26.50 hours after repeated oral dosing in phase 1 studies; the observed half-life supported once-daily administration.

Onset

Median plasma Tmax was approximately 1–2 hours after initial dosing and approximately 2–8 hours after repeated dosing, depending on dose and study.

Administration Routes (Research)

oral

Reported Research Effects

GLP-1 receptor agonism
Dose-dependent reductions in glycemic indices were observed in phase 1 and phase 2 studies in participants with type 2 diabetes.
Reductions in body weight were observed in phase 1 and phase 2 studies in participants with type 2 diabetes or obesity.
Gastrointestinal adverse events, particularly nausea, were among the most frequently reported treatment-emergent events in phase 1 studies.
Elevations in liver transaminases were reported in a subset of participants in later studies, contributing to termination of development.

Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Notes

Phase 1 studies evaluated once-daily oral doses with target doses ranging from 10 to 180 mg/day, using dose titration in several cohorts. One study evaluated starting doses of 20 or 40 mg followed by escalation to 60 or 80 mg. A phase 2 randomized dose-ranging study in type 2 diabetes and obesity was terminated early for safety reasons. Lotiglipron is reported as a small-molecule, nonpeptide GLP-1 receptor agonist; no reliable authoritative storage or solubility specification was identified.

Supplementary research context only. Not medical advice or a treatment recommendation.

Registry Identifiers

CAS 2401892-75-7; PubChem CID 146609022; FDA UNII YI10W1K93A; molecular formula C31H31ClN4O5; molecular weight 575.1 g/mol; InChIKey SVPYZAJTWFQTSM-UGDMGKLASA-N; ChEMBL CHEMBL5314631

Source-Backed Observations

Investigational compound; no approved therapeutic indication identified in the authoritative sources reviewed. Pfizer terminated lotiglipron clinical development in June 2023 following pharmacokinetic findings and laboratory elevations of ALT and/or AST in phase 1 drug-drug-interaction studies and a phase 2 study. The reported abnormalities occurred without reported liver failure in the cited study summary.

Reflects published research. Educational reference — not a recommendation for use.

Sources Under Review

Lotiglipron compound record
https://pubchem.ncbi.nlm.nih.gov/compound/Lotiglipron (accessed 2026-09-12)

Lotiglipron FDA Global Substance Registration System record
https://precision.fda.gov/ginas/app/ui/substances/YI10W1K93A (accessed 2026-09-12)

Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose-ranging, phase 2, randomized, placebo-controlled study
https://pmc.ncbi.nlm.nih.gov/articles/PMC11618248/ (accessed 2026-09-12)

Study Details: NCT05671653
https://clinicaltrials.gov/study/NCT05671653 (accessed 2026-09-12)

Study Details: NCT05788328
https://clinicaltrials.gov/study/NCT05788328 (accessed 2026-09-12)

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.